SCIATICON AB
Patent Owner
Stats
- 0 US PATENTS IN FORCE
- 2 US APPLICATIONS PENDING
- Sep 27, 2012 most recent publication
Details
- 0 Issued Patents
- 0 Issued in last 3 years
- 0 Published in last 3 years
- 124 Total Citation Count
- Jan 17, 2001 Earliest Filing
- 9 Expired/Abandoned/Withdrawn Patents
Patent Activity in the Last 10 Years
Technologies
Intl Class
Technology
Matters
Rank in Class
Top Patents (by citation)
| Upgrade to the Professional Level to View Top Patents for this Owner. Learn More |
Recent Publications
Publication #
Title
Filing Date
Pub Date
Intl Class
2012/0244,157 USE OF TNF-ALPHA INHIBITORS FOR TREATING A NERVE DISORDER MEDIATED BY NUCLEUS PULPOSUSJun 06, 12Sep 27, 12[A61K, A61P]
2012/0093,816 Use of TNF-alpha Inhibitors for Treating a Nerve Disorder Mediated by Nucleus PulposusNov 14, 11Apr 19, 12[A61K, A61P]
Recent Patents
- No Recent Patents to Display
Expired/Abandoned/Withdrawn Patents
Patent #
Title
Status
Filing Date
Issue/Pub Date
Intl Class
8057792 Use of an antibody that blocks TNF-alpha activity for treating a nerve disorder mediated by nucleus pulposusExpiredMar 01, 10Nov 15, 11[A61K, C07K]
7906481 Specific TNF-A inhibitors for treating spinal disorders mediated by nucleous pulposusExpiredJan 03, 07Mar 15, 11[A61K]
7811990 Soluble cytokine receptors TNF-α blocking antibodies for treating spinal disorders mediated by nucleus pulposusExpiredApr 20, 07Oct 12, 10[A61K, C07K]
7723357 Thalidomide and thalidomide derivatives for treating spinal disorders mediated by nucleus pulposusExpiredApr 14, 08May 25, 10[A61K]
7708995 Use of TNF-alpha inhibitors for treating a nerve disorder mediated by nucleus pulposusExpiredSep 14, 06May 04, 10[A61K, C07K]
6635250 Use of certain metalloproteinase inhibitors for treating nerve disorders mediated by nucleus pulpsusExpiredJan 17, 01Oct 21, 03[A61K]
2001/0055,594 Use of certain drugs for treating nerve root injuryAbandonedApr 06, 01Dec 27, 01[A61K]
Top Inventors for This Owner
| Upgrade to the Professional Level to View Top Inventors for this Owner. Learn More |
We are sorry but your current selection exceeds the maximum number of comparisons () for this membership level. Upgrade to our Level for up to -1 comparisons!
We are sorry but your current selection exceeds the maximum number of portfolios (0) for this membership level. Upgrade to our Level for up to -1 portfolios!.